<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02579096</url>
  </required_header>
  <id_info>
    <org_study_id>594</org_study_id>
    <nct_id>NCT02579096</nct_id>
  </id_info>
  <brief_title>Gout: Allopurinol vs. Febuxostat</brief_title>
  <official_title>CSP #594 - Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will compare two effective therapies, allopurinol and febuxostat, to lower serum
      uric acid and therefore prevent further gout attacks. These therapies have never been
      compared at appropriate doses. Further, they will be studied in patients with kidney disease
      for the first time.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gout is the most common form of inflammatory arthritis affecting adults (1), with a disease
      frequency that continues to increase dramatically (2). Gout is associated with substantial
      morbidity and mortality which are concentrated in older men and magnified in patients with
      chronic kidney disease (CKD) (3-6), demographics common to the Veterans Affairs (VA) Health
      System. Effective gout therapies are readily available and are centered primarily on the use
      of approved urate lowering therapy (ULT). Despite having excellent ULT options available to
      patients (7), gout is extremely poorly managed especially in patients with CKD (8-10).

      The two most widely used ULTs in clinical practice, allopurinol and febuxostat, have recently
      been endorsed as the two acceptable first-line treatment strategies in chronic gout (7).
      Although both agents appear to be efficacious and generally well-tolerated, allopurinol and
      febuxostat have significantly different costs and have never been compared to each other at
      appropriate doses. Randomized controlled trials completed to date comparing allopurinol with
      febuxostat in gout have used 'fixed' and, in many cases, insufficient doses of allopurinol
      (11-13), an approach that is contrary to current guideline recommendations (7). Furthermore,
      these studies have included only very small proportions of gout patients with CKD even though
      CKD is present in approximately 1 of every 2 gout sufferers (14).

      To test the hypothesis that allopurinol is non-inferior to febuxostat in the treatment of
      gout, the investigators propose a randomized open-label non-inferiority trial, which for the
      first time compares allopurinol with febuxostat using appropriately titrated doses and a
      &quot;treat-to-target&quot; approach. Further, the investigators will assess the comparative
      effectiveness of these agents in a significant number of gout patients with co-morbid CKD.

      The investigators plan to enroll 950 participants with a diagnosis of gout, including
      participants with stage 3 CKD, who are hyperuricemic defined as a serum uric acid
      concentration (sUA) above 6.8 mg/dl. Participants will be recruited from 18 Veteran Affairs
      and 5 Rheumatology and Arthritis Investigational Network (RAIN) sites. The total duration of
      the trial will be 4 years. Recruitment will occur over 24 months. Participants will be
      followed for 72 weeks. This will include a 24 week Dose Titration Phase (Phase 1) followed by
      a 24 week Maintenance and Optimization Phase (Phase 2) and then a 24 week Steady State Flare
      Observation Phase (Phase 3). The investigators will use a &quot;treat-to-target&quot; approach with
      specified titration of ULT dosing to obtain goal sUA. Maximal daily drug doses will be 800
      mg/day for allopurinol or 120 mg/day for febuxostat.

      The primary outcome will be the proportion of participants who have at least one gout flare
      in the allopurinol group compared to the febuxostat group during Phase 3. This primary
      outcome was endorsed by the patient and VA provider groups that were surveyed (see below).
      All participants will be followed during Phase 3 regardless of the achievement of sUA goal.
      The primary hypothesis will test the non-inferiority of allopurinol with regards to
      proportions of flares. The investigators anticipate that approximately 15 to 20% of patients
      will flare during Phase 3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 26, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of participants who have at least one gout flare in the allopurinol group compared to the febuxostat group</measure>
    <time_frame>Phase III of the study (months 12-18 of study duration)</time_frame>
    <description>Proportion of participants who have at least one gout flare in the allopurinol group compared to the febuxostat group</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">950</enrollment>
  <condition>Gout</condition>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be titrated up to the dose that will lower to target uric acid levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Febuxostat)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo in the shape of Febuxostat will be given with allopurinol</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Febuxostat will be titrated up to the dose that will lower to target uric acid levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Allopurinol)</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Placebo in the shape of Allopurinol will be given with Febuxostat</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Allopurinol</intervention_name>
    <description>Patients will be titrated up to the dose that will lower to target uric acid levels.</description>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_label>Placebo (Febuxostat)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Febuxostat</intervention_name>
    <description>Febuxostat will be titrated up to the dose that will lower to target uric acid levels.</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_label>Placebo (Allopurinol)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, vehicle control (Febuxostat-shaped)</intervention_name>
    <description>Placebo in the shape of Febuxostat will be given with Allopurinol</description>
    <arm_group_label>Allopurinol</arm_group_label>
    <arm_group_label>Placebo (Febuxostat)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo, vehicle control (Allopurinol-shaped)</intervention_name>
    <description>Placebo in the shape of Allopurinol will be given with Febuxostat</description>
    <arm_group_label>Febuxostat</arm_group_label>
    <arm_group_label>Placebo (Allopurinol)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 years

          -  History of gout - crystal proven or historical as defined by ACR criteria listed above

          -  Serum urate level 6.8 mg/dl

        Exclusion Criteria:

          -  Stage 4 or 5 Chronic Kidney Disease (CKD) - defined as eGFR of &lt;30 ml/min

          -  Women less than 50 years of age

          -  Patients with a history of prior solid organ / hematopoietic transplantation

          -  Previous allergy or intolerance to allopurinol or febuxostat

          -  Patients who are not candidates for any of the recommended prophylactic medications
             (colchicine, naprosyn or glucocorticoids)

          -  Patients who in the opinion of the investigator have a high genetic risk for
             allopurinol hypersensitivity syndrome (AHS*) unless they have been found to be
             negative for HLA B5801.

          -  Previous history of failure to reach target uric acid levels despite therapy with
             allopurinol at dose &gt; 300 mg/day

          -  Prior febuxostat use

          -  Patients with malignancies that are currently active with exception of non-melanoma
             skin cancer

          -  Patients with serum uric acid levels &gt;15 mg/dl

          -  Patients with myelodysplasia and hemoglobin of &lt; 8.5 g/dL

          -  Patients with chronic liver disease with more than one of the following:

               -  INR 1.7, not on Warfarin therapy

               -  Bilirubin 2 mg/dL

               -  Serum albumin &lt;3.5 g/dL

               -  Ascites

               -  Encephalopathy

          -  Current use of azathioprine, mercaptopurine, didanosine, cyclophosphamide, or
             probenecid

          -  Patient who are unable to give informed consent

          -  Enrollment in another randomized interventional clinical trial

          -  Any severe medical condition that, in the enrollee's opinion, is likely to compromise
             the participant's ability to complete the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James R O'Dell</last_name>
    <role>Study Chair</role>
    <affiliation>Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Penelope A Macht, MPH</last_name>
    <phone>(857) 364-5493</phone>
    <email>penelope.macht@va.gov</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary T Brophy, MD</last_name>
    <phone>(857) 364-5415</phone>
    <email>Mary.Brophy@va.gov</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>VA Loma Linda Healthcare System, Loma Linda, CA</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92357</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald S Fernando</last_name>
      <phone>909-583-6361</phone>
      <email>ronald.fernando@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System, San Diego, CA</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Terkeltaub</last_name>
      <phone>858-642-3247</phone>
      <email>rterkeltaub@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>San Francisco VA Medical Center, San Francisco, CA</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>David Daikh</last_name>
      <phone>415-750-2104</phone>
      <email>David.Daikh@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Miami VA Healthcare System, Miami, FL</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leonardo Tamariz</last_name>
      <phone>305-575-7000</phone>
      <phone_ext>4487</phone_ext>
      <email>Leonardo.Tamariz@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Edward Hines Jr. VA Hospital, Hines, IL</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141-5000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rochella Ostrowski, MD</last_name>
      <phone>708-202-1515</phone>
      <email>rochella.ostrowski@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iowa City VA Health Care System, Iowa City, IA</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52246-2208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ted Mikuls</last_name>
      <phone>402-559-7288</phone>
      <email>tmikuls@unmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain, MA</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Monach</last_name>
      <phone>857-364-5552</phone>
      <email>Paul.Monach@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Minneapolis VA Health Care System, Minneapolis, MN</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hollis Krug</last_name>
      <phone>612-467-4198</phone>
      <email>hollis.krug@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kansas City VA Medical Center, Kansas City, MO</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damandeep Walia</last_name>
      <phone>816-861-4700</phone>
      <phone_ext>57052</phone_ext>
      <email>Damandeep.Walia@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105-1873</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James R O'Dell</last_name>
      <phone>402-346-8800</phone>
      <phone_ext>5359</phone_ext>
      <email>James.O'Dell@va.gov</email>
    </contact>
    <contact_backup>
      <last_name>Jefferey A Newcomb, BA</last_name>
      <phone>(402) 995-4215</phone>
      <email>Jefferey.Newcomb@va.gov</email>
    </contact_backup>
    <investigator>
      <last_name>James R O'Dell</last_name>
      <role>Study Chair</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhattan Campus of the VA NY Harbor Healthcare System, New York, NY</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michael Pillinger</last_name>
      <phone>212-951-3328</phone>
      <email>michael.pillinger@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Asheville VA Medical Center, Asheville, NC</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28805</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jack Work</last_name>
      <phone>828-298-7911</phone>
      <phone_ext>4164</phone_ext>
      <email>jack.work@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center, Cincinnati, OH</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Beary</last_name>
      <phone>513-558-1036</phone>
      <email>John.Beary@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Portland Health Care System, Portland, OR</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pascale Schwab</last_name>
      <phone>503-220-8262</phone>
      <phone_ext>55603</phone_ext>
      <email>Pascale.Schwab@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Philadelphia VA Medical Center, Philadelphia, PA</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joshua Baker</last_name>
      <phone>215-823-5251</phone>
      <email>joshua.baker@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John S Richards</last_name>
      <phone>412-360-6146</phone>
      <email>John.Richards1@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System Dallas VA Medical Center, Dallas, TX</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Reimold</last_name>
      <phone>214-857-4230</phone>
      <email>andreas.reimold@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>VA Salt Lake City Health Care System, Salt Lake City, UT</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84148</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Battistone</last_name>
      <phone>801-582-1565</phone>
      <phone_ext>1277</phone_ext>
      <email>Michael.Battistone@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>White River Junction VA Medical Center, White River Junction, VT</name>
      <address>
        <city>White River Junction</city>
        <state>Vermont</state>
        <zip>05009-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Taylor</last_name>
      <phone>802-295-9363</phone>
      <phone_ext>5491</phone_ext>
      <email>Tom.Taylor@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Salem VA Medical Center, Salem, VA</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ali Iranmanesh</last_name>
      <phone>540-982-2463</phone>
      <phone_ext>1071</phone_ext>
      <email>ali.iranmanesh@va.gov</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2015</study_first_submitted>
  <study_first_submitted_qc>October 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2015</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gout</keyword>
  <keyword>Allopurinol</keyword>
  <keyword>Febuxostat</keyword>
  <keyword>CKD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Gout</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Allopurinol</mesh_term>
    <mesh_term>Febuxostat</mesh_term>
    <mesh_term>Uric Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

